文献速递慢性肾脏病

替戈拉生与质子泵抑制剂使用者慢性肾脏病风险比较

CKD risk with tegoprazan versus proton pump inhibitors.
PubMed 文献 · Nephrol Dial Transplant · 2026-09-04

该研究基于韩国全国人群数据库,纳入2020—2021年新使用替戈拉生或质子泵抑制剂(PPI)且无既往肾病的成人,经1:3倾向评分匹配后用Cox模型比较新发慢性肾脏病(CKD)风险。结果PPI组CKD发生率高于替戈拉生组(6.16 vs 4.63/1000人年),匹配后PPI起始与更高CKD风险相关(HR 1.22;95%CI 1.09-1.37;P<0.01)。

要点

  • PPI起始者新发CKD风险高于替戈拉生起始者(HR 1.22)。
  • 亚组与敏感性分析结果一致,非匹配队列HR 1.34。
  • 长期抑酸需权衡肾脏安全性、疗效与成本。

核心结论

  • 在大型真实世界分析中,PPI起始与新编码CKD发生率高于替戈拉生起始相关。

研究设计与样本

  • 基于韩国健康保险审查评估数据库的全国人群队列,纳入2020—2021年新使用替戈拉生或PPI且无既往肾病的成人。
  • 共901,606例新使用者(替戈拉生43,864例;PPI 857,742例),经1:3倾向评分匹配后用Cox比例风险模型比较新发CKD风险。

主要发现

  • PPI组CKD发生率为6.16/1000人年,替戈拉生组为4.63/1000人年。
  • 匹配队列中PPI起始较替戈拉生起始的CKD风险更高(HR 1.22;95%CI 1.09-1.37;P<0.01)。
  • 非匹配队列结果一致(HR 1.34;95%CI 1.20-1.48;P<0.01),亚组与敏感性分析结果一致。

临床怎么用

  • 需长期抑酸治疗时,可将肾脏损伤风险作为选择PPI或替戈拉生的考量之一,同时兼顾疗效与成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Proton pump inhibitors (PPIs) are widely used for acid suppression but have been associated with kidney injury. Potassium-competitive acid blockers (P-CABs) such as tegoprazan provide rapid, reversible inhibition of gastric H⁺/K⁺-ATPase, yet their renal safety remains unclear. We compared the risk of incident chronic kidney disease (CKD) between tegoprazan and PPIs in a nationwide population-based cohort. METHODS: Using the Korean Health Insurance Review and Assessment database, we identified adults without prior kidney disease who initiated tegoprazan or a PPI during 2020-2021. After 1:3 propensity score matching, we compared the risk of incident CKD using Cox proportional hazards models. Sensitivity and subgroup analyses examined robustness and effect modification by age, sex, and comorbidities. RESULTS: Among 901,606 new users (43,864 tegoprazan; 857,742 PPIs), PPI use was associated with a higher CKD incidence (6.16 vs 4.63 per 1,000 person-years). In the matched cohort, PPI initiation was associated with a higher risk of CKD than tegoprazan initiation (hazard ratio 1.22; 95% CI 1.09-1.37; P < 0.01). Findings were consistent across subgroups and sensitivity analyses, including the unmatched cohort (HR 1.34; 95% CI 1.20-1.48; P < 0.01). CONCLUSION: In this large real-world analysis, PPI initiation was associated with a higher rate of newly coded CKD than tegoprazan initiation. These findings provide comparative kidney safety data and suggest that risk of kidney injury may be one consideration, alongside efficacy and cost, when prolonged acid suppression is required.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Kim SY, Kim HS, Lee TS, et al. CKD risk with tegoprazan versus proton pump inhibitors. Nephrol Dial Transplant. 2026. PMID: 42695987. doi:10.1093/ndt/gfag206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。